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Abstract 
Background: Insulin-like growth factor-I (IGF-I) is used to screen for acromegaly in diabetic 
cats. In humans, most circulating IGF-I forms ternary complexes (TC) with IGF-binding protein 
(IGFBP-3) and an acid-labile subunit. Compared to humans, the amount of TC in cats is more 
variable. IGF-I concentrations are reported to increase during insulin treatment, more rapidly in 
cats achieving remission. 
Objectives: To investigate (i) factors associated with circulating IGF-I concentrations, including 
IGF-binding protein profiles (ii) effect of insulin treatment on IGF-I concentrations and (ii) IGF-I 
as prognostic marker of DM remission. 
Animals: 31 privately-owned diabetic cats of which 24 were followed 1 year, and 13 healthy 
cats. 
Methods: In this prospective study, insulin, IGF-I, glucose and fructosamine were measured. 
IGF-binding forms were determined by chromatography in 14 diabetic and 13 healthy cats. IGF-
I, IGF-II, IGFBP-3 and IGFBP-5 was measured by mass spectrometry in 3 cats achieving 
remission. 
Results: IGF-I median (interquartile range) before start of insulin treatment was 300 (160-556) 
ng/mL. IGF-I was positively associated with TC (p<0.0001) and endogenous insulin (p=0.005) 
and negatively associated with fructosamine (p<0.0001). IGF-I was 2-fold higher 2-4 weeks 
after start of insulin treatment compared with baseline (p=0.0001) and predicted future 
remission (p=0.046). In cats that went into remission, the amount of TC and IGFBP-3 increased, 
suggesting the increase in IGF-I is dependent on TC formation. 
Conclusions: Insulin treatment should be accounted for when interpreting IGF-I in diabetic 
cats. IGF-I 2-4 weeks after initiation of insulin treatment shows promise as prognostic marker for 
remission in diabetic cats. 
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Insulin-like growth factors (IGF-I and -II) and a family of six high affinity binding proteins (IGFBP-
1 to -6) are important for growth and metabolism. In adult humans, >90% of IGFs are 
associated in a high affinity, GH-dependent, 150kDa complex with IGFBP-3 or IGFBP-5 and a 
third protein, the acid-labile subunit (ALS).1,2 Formation of these ternary complexes (TC) 
prolongs the half-life of IGFs and is therefore a major determinant of circulating concentrations.1 
The stability of the complexes also makes IGF-I a good diagnostic marker of growth hormone 
excess. In adult humans, ALS circulates in excess of the TC and is therefore not a limiting factor 
for TC formation.3 One study demonstrated that ALS was a limiting factor for TC formation in 
healthy cats, while in diabetic cats with high IGF-I concentrations, ALS apparently circulated in 
excess.4   
Measurement of feline IGF-I is mainly used as a screening marker for acromegaly, which 
is almost exclusively diagnosed in cats with diabetes mellitus (DM).5  Feline DM is considered to 
be similar to human type 2 DM and is characterized by insulin resistance and beta-cell failure.6 
The insulin-secreting capacity of feline beta-cells is blunted during hyperglycaemia7 and insulin 
concentrations at diagnosis of DM are usually low.8,9 Despite low insulin concentrations at 
diagnosis, cats can go into remission, defined as independence of insulin treatment >4 weeks.10 
Insulin concentrations at diagnosis do not predict remission.10,11 Insulin treatment of feline DM 
has been observed to increase IGF-I12,13 which normalized faster in cats achieving remission.13 
As in other species, feline IGF-I concentrations appear to be influenced by nutritional status.14 
Improved understanding of the IGF-system and the effect of insulin treatment is therefore 
essential for interpretation of IGF-I measurements in cats with DM. 
The aim of this study was to further characterize the IGF-system in cats with DM by 
determining (i) factors associated with circulating IGF-I concentrations, including IGF-binding 
protein profiles (ii) the effect of insulin treatment on IGF-I concentrations and (ii) serum IGF-I as 
prognostic marker of DM remission. 
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Material and Methods 
Animals 
This study was approved by the Swedish Animal Ethics Committee and the Swedish Board of 
Agriculture (C301/10, C22/9, 31-105551/10 and 31-1364/09). All cat owners provided informed 
written consent. In total serum from 31 cats diagnosed with DM and 13 healthy cats was used 
(Fig 1). Cats were enrolled at Bagarmossen Animal Hospital in Stockholm, the University Animal 
Hospital in Uppsala and at four smaller clinics in Stockholm. Diagnosis of DM was based on 
clinical signs, hyperglycaemia >162 mg/dL detected in >2 evaluations and elevated 
fructosamine (>350 µmol/L). Cats were excluded from the study if they were pregnant or age <1 
year. 
For evaluation of IGF-binding profiles an initial blood sample was collected from 17 
diabetic cats. In addition samples from healthy cats used for a previous study15 were eligible for 
the laboratory work. These cats were considered healthy based on a questionnaire, physical 
exam and a basic biochemical profile (glucose, fructosamine, creatinine, ALT, albumin, protein). 
For IGF-binding profiles, 7 samples from cats with DM and 13 healthy cats were chosen to 
represent at range of IGF-I concentrations in both healthy and diabetic cats, thereby excluding 
10 of the DM cats (Fig 1). IGF-I concentrations did not differ between excluded and included 
cats (p=0.65).  Six of the cats with DM were sampled before insulin treatment and one cat was 
receiving insulin glargine. 
Twenty-four cats diagnosed with DM but not yet on insulin treatment were enrolled in the 
longitudinal study. A management regime that included insulin treatment was required for 
inclusion. Cats were followed for a year from inclusion in the study or until remission, death or 
loss to follow up. Blood samples were taken five times: before first insulin injection (T0), after 2-
4 weeks (T1), 8-10 weeks (T2), 5-7 months (T3) and 10-13 months (T4). At T0 cats were fasted 
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for at least 12 h, and at T1-T4 for at least 5 h. At T1-T4, all cats were given insulin q12h and 
blood sampling was performed by venipuncture into tubes without anticoagulant. The duration of 
effect of insulin glargine in cats is estimated to be approximately 11h.16 Therefore, to minimize 
the interference of insulin glargine in the insulin assay, blood was taken just before the next 
q12h insulin injection. At every sampling occasion the veterinary practitioner performed a 
standardized clinical examination and completed a questionnaire. Body composition was 
evaluated by body condition score (BCS) and graded 1-5 with 1 being underweight and 5 
overweight.17 The treating veterinarian decided about additional diagnostic tests and thus not all 
cats had the same diagnostic-work-up. 
Remission from DM was defined as no insulin treatment for one month, no clinical signs 
of DM and fructosamine concentrations within the reference interval (<350 µmol/L). Owners of 
cats that were euthanized during the study (n=4) or after (n=2) were asked for permission for 
post-mortem examination and all but one gave this permission. Post-mortem examinations were 
performed by the same board-certified pathologist. Early in the study period, CT with contrast 
enhancement of the pituitary gland was done in one cat with IGF-I >1000 ng/mL, when 
anaesthetized for dental treatment. 
Analytical procedures 
Blood samples were centrifuged within 30-60 minutes of sampling. Serum was aliquoted into 
two tubes. One aliquot was sent by post at ambient temperature for analysis of glucose and 
fructosamine at the Clinical Pathology Laboratory at the Swedish University Animal Hospital. 
Glucose was analyzed using hexokinase/glucose-6-phosphate dehydrogenasea and 
fructosamine by the nitrotetrazolium blue-methodb using a standard biochemistry instrument.c 
The laboratory reported intra- and inter-assay CVs for glucose of 0.6 and 1.1%, respectively, 
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and for fructosamine 0.2 and 1.6%, respectively. The laboratory reported that serum glucose 
concentrations varied between -0.3 and 6.6% (n=7 samples) when stored at room temperature 
for two days and that fructosamine concentrations varied between -3.9 and 4.1% (n=3 samples) 
when stored at room temperature for three days. All samples arrived at the laboratory within two 
days. 
The other serum aliquot was immediately frozen at -20°C, or kept at 2-4°C and frozen 
within 20h, and used for analysis of insulin and IGF-I. Feline insulin concentrations are stable for 
4 days when stored at 2-4°C.9 IGF-I concentrations in samples (n=2) stored at 2-4°C and 
analyzed after 3 and 6 days varied between -1.7 and 6.0% compared to baseline. IGF-I and 
insulin were measured with ELISAsd,e previously validated for use in cats.9,15 There is a cross-
reactivity of 8.4% for insulin glargine in the feline insulin ELISA.18 Intra- and inter-assay CVs of 
the insulin assay were 2.0-5.8% and 7.6-13.7%, respectively. Intra- and inter-assay CVs of the 
IGF-I assay were 2.4-4.8% and 3.6-5%, respectively. For both ELISAs, multiple samples from 
the same cat were analyzed together on the same ELISA plate. 
Size-exclusion chromatography 
Size separation chromatography was performed on the single serum samples from healthy cats 
(n=13) and diabetic cats (n=7), as well as on samples from diabetic cats sampled at T0 and T1 
(n=7). To visualize the IGF-binding protein profile in serum, samples were incubated with 
radioiodinated human IGF-II (125I-IGF-II)f under neutral conditions, as previously described.4,19 
Tracer concentrations of 125I-IGF-II, estimated <0.001% of total IGF concentration, were used to
reflect the endogenous IGF-binding profile without disturbing the kinetics of the interactions 
between endogenous IGFs and IGF-binding proteins. Samples were therefore incubated until 
equilibrium was reached (17 h at 4°C). In total, 25 µL of serum (containing 50 000 cpm 125I-IGF-
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II, 1096 Ci/mmol, in a final volume of 100 µL of PBS (0.05 mol L-1, pH 7.4) were loaded on a 
Superose 12 columng and eluted at 0.5 mL/min. Fractions were collected every 30 sec and 
radioactivity counted using a gamma counter.h 
In another analysis serum was also size-fractionated, and fractions were analyzed for 
immunoreactive IGF-I using an IGF-I ELISA. This analysis was performed on serum from 2 
healthy cats and one diabetic cat treated with insulin. The samples were diluted to 50% v/v with 
ammonium acetate (0.2 mol L-1, pH 7.4). In total 100 µL serum in a final volume of 200 µL were 
size-separated under neutral conditions using ammonium acetate (0.2 mol L-1, pH 7.4) as 
running buffer. Fractions were collected every 60 sec and dried by vacuum concentration. The 
fractions were analyzed with the IGF-I ELISA according to the manufacturer´s recommendation 
except that assay buffer was added directly to the dried fractions. 
Mass spectrometry 
A targeted mass spectrometry-based method (MS), previously validated for cats,20 was applied 
to determine the concentrations of IGF-I, IGF-II, IGFBP-3 and IGFBP-5 in 3 cats with DM later 
achieving remission. Analyses were performed in serum at T0 and T1 exactly as described by 
Sundberg et al.20  Briefly, the serum proteins were digested with trypsin and isotopically labelled 
internal standards, four QPrESTsi and one synthetic peptidej, were added to the samples. The 
tryptic peptides were separated in reversed phase on an EASY-nLC 1000 systemk and 
electrosprayed on-line to a QExactive Plus Orbitrap mass spectrometerl operating in parallel 
reaction monitoring (PRM) mode. The Skyline softwarem was applied for data analysis and 
quantification. 
Statistical analysis 
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IGF-binding forms and concentrations of IGF-I, IGF-II, IGFBP-3 and IGFBP-5 measured by 
mass spectrometry 
As previously described,4 the amount of 125I-IGF-II incorporated into the 150kDa molecular mass
form was used as a marker for the relative amount of endogenous 150kDa-TC, while the 30-
50kDa complex reflected binary forms. The 150kDa and 30-50kDa peaks were expressed as a 
150/30-50kDa ratio which was estimated as a ratio of the sums of the five top-fractions for the 
150kDa peak and 30-50kDa peak, respectively. 
The association between IGF-I, age, sex, concurrent diseases and the relative amount 
of the 150kDa complex (the 150kDa/30-50kDa ratio) was evaluated by univariate linear 
regression analysis in a combined analysis of healthy cats (n=13) and diabetic cats before 
insulin treatment (n=13). Preliminary models showed non-normality of the residuals and the 
150kDa/30-50kDa ratio was transformed to the natural logarithmic scale. 
Differences between healthy and DM cats used for IGF-binding profiles were evaluated 
by Mann-Whitney test. In cats with DM sampled at T0 and T1, changes in the 150kDa/30-50kDa 
ratio as well as IGFBP-3, IGFBP-5 and IGF-II were evaluated by paired t-test after 
transformation to the natural logarithmic scale. 
Predictors of IGF-I concentrations 
To evaluate factors associated with IGF-I concentrations, a linear mixed-effect model was built 
using the statistical software R.n Potential predictors were age, concurrent diseases, days from 
T0, insulin, fructosamine, BCS and weight. Akaike Information Criteria and p-values were 
evaluated during modelling and predictors that did not contribute significantly to the model 
(p>0.10) were excluded. Residuals were evaluated for normal distribution, homoscedasticity 
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and linearity with respect to the predictors. Preliminary models showed non-normality of 
residuals and insulin and fructosamine were hence transformed to the natural logarithmic scale. 
Predictors of remission 
Predictors of remission were evaluated by univariate logistic regression and receiver operating 
characteristic (ROC) curves, to calculate area under the curve (AUC). Since remission of 
diabetes has been associated with tight glycaemic control,21 glucose, fructosamine and insulin 
were considered potential predictors in addition to IGF-I. The statistical software R was used for 
logistic regression analyses.n 
Results 
IGF-binding forms and concentrations of IGFBP-3, IGFBP-5, IGF-II and IGF-I by mass 
spectrometry 
Cats with DM used for evaluating IGF-binding forms were sampled once before insulin 
treatment and consisted of 2 castrated male cats, 3 castrated female cats and 1 intact male cat. 
Cats were between 8.2 and 20 years old and weighed between 3.9 and 6.3 kg. One cat had 
received glucocorticoids intratumoural in a cutaneous mast cell tumor before being diagnosed 
with DM and had renal insufficiency. One cat had cremor dentis and was obese, and two had 
urinary tract infection. No cat had elevated TT4. Glucose and fructosamine ranged from 19.5 to 
33.3 mmol/L and 483 to 725 µmol/L respectively. Healthy cats consisted of 5 castrated males, 5 
castrated females, 1 intact male and 2 intact females. Age ranged from 4.2 to 8.6 years and 
weight was between 3.0 and 7.1 kg. There was no significant difference in weight (p=0.21) or 
IGF-I concentrations (p=0.68) between healthy and DM cats used for size exclusion 
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chromatography, but DM cats were significantly older (p<0.001). Figure 2 shows the IGF-
binding profiles in these 13 healthy cats and 6 diabetic cats sampled before insulin treatment, 
and presented for three equal IGF-I intervals generated based on a previously published 
reference interval for healthy cats (90-1207 ng/mL).15 125I-IGF-II-tracer incorporated into 150kDa
complexes reflect the proportion of endogenous IGFs circulating in a TC with IGFBP-3/5 and 
ALS, while relatively more tracer incorporation into 30-50kDa complexes represents the amount 
of endogenous binary complexes. In univariate linear regression analyses with IGF-I and ln-
150/30kDa ratio, the regression lines showed no statistical differences in slope (p=0.89) or 
intercept (p=0.29) between healthy and diabetic cats, suggesting a similar IGF distribution 
across ternary and binary complexes between healthy and diabetic cats across the range of 
IGF-I concentrations. In a combined analysis with both healthy and diabetic cats the ln-150/30-
50kDa ratio was correlated to IGF-I (p<0.001, R2 52.4%)(Fig 3) but not to age (p=0.83), 
concurrent diseases (p=0.48) or sex (p=0.57). 
Serum was also size-separated in the absence of 125I-IGF-II and IGF-I immunoreactivity
was determined by the ELISA in 2 healthy cats and in 1 cat on insulin treatment. In fractions 
where 150kDa and 30-50kDa 125I-IGF-II-binding peaks elute, immunoreactive IGF-I was 
detected mainly in the 150kDa complex regardless of relative size of the 30-50kDa peak after 
size-separation with 125I-IGF-II-tracer (data not shown). 
Changes in IGF-binding profiles were determined in a longitudinal study. The largest 
increment in IGF-I concentrations was between T0 and T1 (Fig 4), therefore the distribution of 
IGF-binding forms at these two sampling occasions was investigated. At T0, the proportion of 
125I-IGF-II incorporated into the 150kDa complex was low in relation to the 30-50kDa complex
both in cats that went into remission (Fig 5a) and in cats that did not go into remission (Fig 6a). 
During treatment, a relative increase of 125I-IGF-II binding in the 150kDa complex was observed
in the three cats that went into remission (p=0.03, Fig 5b) but not in those that did not achieve 
remission (p=0.7, Fig 6b). Concentrations of IGF-I, IGF-II, IGFBP-3 and IGFBP-5, all measured 
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by MS, are shown in Figure 5. In the three cats which went into remission, IGFBP-3 
concentrations increased between T0 and T1 (p=0.03). IGF-II and IGFBP-5 did not differ 
between sampling occasions (p=0.4 and p=0.6, respectively). IGF-II was 2-8-fold higher than 
IGF-I. The molar ratio of IGFBP-3 and IGFBP-5 to total IGFs was 0.55 -1.1. 
Cats included in the longitudinal study 
Seventeen males (16 neutered and 1 intact) and 7 females (all ovariohysterectomised) were 
eligible for the longitudinal study. During the study period cats were followed for a year (n=11) or 
until remission (n=7), death (n=4) or loss to follow up at T2 or T4 (n=2) (Fig 1).  Concurrent 
diseases were diagnosed in 13 cats and consisted of heart disease (n=2), hyperthyroidism 
(n=3), urinary tract infection (n=3) of which one cat also had tooth resorption, pancreatitis (n=2), 
chronic renal failure (n=1), osteoarthritis (n=1) and feline asthma (n=1). The cat with feline 
asthma was treated with fluticasone inhalation. In 18 of the 24 cats TT4 was measured at 
diagnosis of DM. In the remaining 6 cats TT4 was analyzed in samples taken at T0 and saved 
at -80°C and analyzed after study ending. One of these cats had high TT4 (64 nmol/L, reference 
interval 14-45 nmol/L) which was unrecognized during the study. Two cats that had previously 
been treated for DM, went into remission 15 and 26 months prior to study entry, and were 
diagnosed with DM again. Two cats were ketoacidotic and were initially treated with short-acting 
insulin intravenously. One of these cats was euthanized within 24h. Insulin glarginem was used 
in 22 cats and isophane insulinn in one cat. Owners of 15 cats used home monitoring with 
portable blood glucose meters. Veterinarians instructed owners to perform blood glucose curves 
at intervals varying from before every injection to 1 curve every 14 days. These 15 cats, and the 
other 9 cats, were also monitored by fructosamine and clinical signs. The surviving cat with 
ketoacidosis had been treated with glipizide but did not respond to treatment and had 
concurrent hyperthyroidism. This cat, and one additional cat with hyperthyroidism, were 
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receiving oral antithyroid medication (thiamazole). At T0, 2 cats were scored as underweight 
(BCS 1-2), 10 cats as normal weight (BCS 3) and 12 cats as overweight (BCS 4-5). 
Descriptive statistics for the cats are presented in Table 1. IGF-I concentrations 
increased significantly between T0 and T1 (p=0.0001) but did not change significantly 
thereafter. Seven cats went into remission during the study period, all within five months from 
T0 (Fig 4).  Of the 24 cats, eight (33%) had IGF-I concentrations >1000 ng/mL, a cut-off that is 
used when screening for acromegaly,22,23 on at least one sampling occasion during the study. 
Five of the eight cats with IGF-I >1000 ng/mL achieved remission. Diagnostic imaging of the 
pituitary gland of one of these cats did not show any abnormalities and there were no clinical 
signs of acromegaly. Two additional cats with IGF-I >1000 ng/mL were subjected to post-
mortem examinations with no findings suggestive of acromegaly. One female cat with IGF-I 
concentrations between 514 and 956 ng/mL had a pituitary adenoma on post-mortem 
examinations, however no immunohistochemistry was performed. This cat had no clinical signs 
of acromegaly noted by the veterinary practitioner and was on less than 0.2 IU/kg insulin q12h 
and was therefore not considered insulin resistant (defined as >1.5 IU/kg per dose).24  
One cat sampled at T4 had serum insulin concentrations well above the other cats (Fig 
4). At this sampling occasion the cat had a glucose concentration of 58 mg/dL, fructosamine 
478 µmol/L and was on insulin glargine 0.6 IU/kg q12. The sample was reanalyzed twice with 
the same results. 
Predictors of IGF-I concentrations 
The mean increase in IGF-I between T0 and T1 was estimated to 350 ng/mL (95% CI 200-500). 
It was included as an offset in the model for predictors of IGF-I concentrations to account for 
possible selection bias caused by fallout due to remission. Weight was positively correlated and 
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fructosamine negatively correlated with IGF. However, fructosamine and weight were negatively 
correlated and we excluded weight because fructosamine was found to be a better predictor 
based on Akaike Information Criteria and p-values. As seen in Table 2, IGF-I concentrations 
were negatively associated with ln-fructosamine (p<0.0001) and positively associated with ln-
insulin (p=0.005). The positive association between IGF-I and ln-insulin was linear up to an 
insulin concentration of 60 ng/L but no association was found at higher insulin concentrations. 
Age was not significantly associated with IGF-I (p=0.052) but improved the model fit and was 
kept in the model. Days from T0, BCS and concurrent diseases were not significantly 
associated with IGF-I and were excluded. In the final model, at insulin concentrations up to 60 
ng/L, a doubling of insulin concentration was associated with an estimated increase in IGF-I of 
95 ng/mL. An increase of fructosamine by 10% was associated with an estimated decrease of 
IGF-I by 47 ng/mL. 
Predictors of remission 
There was substantial overlap in IGF-I concentrations between groups at T0 and none of the 
biomarkers at T0 predicted remission. At T1, 22 diabetic cats remained in the study and of these 
six later went into remission. One cat achieved remission before T1 and was not available for 
the prediction model. IGF-I at T1 was associated with remission (p=0.046) but glucose, 
fructosamine and endogenous insulin were not (p=0.11, p=0.24 and 0.31, respectively). The 
estimated AUC in the ROC analysis for IGF-I was 0.80 (CI 0.62-0.99); for glucose 0.76 (CI 0.54-
0.97); for fructosamine 0.65 (CI 0.39-0.90); and for insulin 0.61 (CI 0.33-0.90) (Fig 7). 
Discussion 
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This study contributes to the understanding of the IGF system and its regulation in cats. Total 
IGF-I concentrations in serum were positively associated with the amount of IGF binding in a 
150kDa TC, with lower IGF-I levels associated with relatively more binary IGF-IGFBP 
complexes. Furthermore, IGF-I concentrations were increased at 2-4 weeks after initiation of 
insulin treatment and higher IGF-I concentrations at this time-point were associated with 
remission from DM. An increase in circulating IGF-I with treatment was accompanied by a shift 
to increased amounts of TC compared to binding in lower molecular mass binary complexes. 
Consistent with this shift, IGFBP-3 concentrations were also observed to increase. It is therefore 
recommended that, when using IGF-I as a marker of GH status in cats with diabetes, the effect 
of insulin treatment on IGF-I should be taken into account. 
IGF-binding forms 
Most 150kDa complexes are formed of a high-affinity association between IGF-I or IGF-II and 
IGFBP-3 or IGFBP-5, and a lower-affinity association of ALS with these binary complexes.25,26 
The resulting TC cannot pass the endothelial barrier and are retained in the circulation, with a 
half-life of more than 12 h.1 If sufficient ALS is available therefore, these TC contribute to the 
concentrations of IGF-I and IGF-II in the circulation. Under conditions of limited ALS availability, 
relatively more IGFs circulate in binary complex forms,27 with a circulating half-life of hours.1 
This appears to be the case in cats with lower IGF-I concentrations. Therefore, we speculate 
that the wide variation in the amount of TC may be due to ALS not circulating in excess in many 
cats. The assumption has been made that in cats IGFBP-3 has a high affinity for IGF-I and IGF-
II, similar to humans. While the affinity constants of feline IGFs and IGFBPs are not known, 
similar patterns of IGF-binding in the circulation are seen in other species.28 In contrast to 
previously published results in cats where increased 150kDa/30-50kDa ratio was seen in 
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diabetic cats but not in healthy cats,4 we saw a distribution of higher and lower molecular mass 
forms of IGF-binding in both healthy and diabetic cats. Furthermore, we observed that total IGF-
I concentrations were positively associated with the relative amount of 150kDa complex. The 
discrepancy is explained by the fact that our population of cats, in contrast to the previous study, 
included a wide range of IGF-I concentrations. 
When serum was size-separated and the fractions measured in an IGF-I ELISA, 
immunoreactivity was detected mainly in the 150kDa complex regardless of the amount of 30-
50kDa complex. The ELISA measures only IGF-I whereas size-separation after adding 
iodinated IGF-II will reflect the amount of both IGF-I and IGF-II. Since IGF-I immunoreactivity 
was mainly found in the 150kDa form, and assuming the affinities and concentrations of IGFBPs 
are similar to other species, it is likely that the 30-50kDa peak reflects binary complexes with 
endogenous IGF-II. However, IGF-I and IGF-II affinities in the cat have not been studied and it 
is possible that radioiodinated human IGF-II has a different affinity for feline IGFBPs than feline 
IGF-II, which would affect interpretation of the results. Nevertheless, we chose to use the same 
methodology as previously used for studying feline IGF-binding forms.4 Labeled human IGFs 
have been used for detection of feline IGFBPs on western ligand blots.4,14,15 There is a report of 
similar finding of IGF-I immunoreactivity detected mainly in the 150kDa-peak, regardless the 
size of the 150kDa and 30-50kDa-peak, in children.29  
IGF-I, IGF-II, IGFBP-3 and IGFBP-5 were also measured by mass spectrometry in three 
cats at baseline, and after diabetes remission. In these animals the increase in IGF-I was 
accompanied by an increase in IGFBP-3 concentrations. IGF-I and IGFBP-3 depend on each 
other for TC formation and stability in the circulation which prolongs their half-lives.1 The 
increase in IGFBP-3 and IGF-I may be explained by an increase in ALS, or a direct stimulatory 
effect of insulin treatment on IGF-I and IGFBP-3 in the presence of sufficient ALS. As in 
humans,30 IGFBP-5 in these cats circulated in lower concentrations than IGFBP-3. In humans 
binary complexes with IGFs and IGFBP-5 have a lower affinity for ALS than binary complexes 
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with IGFBP-3.26 If feline IGFBP-5 binary complexes have a similarly lower affinity for ALS,26 our 
results suggest it is unlikely that IGFBP-5 is a major contributor to TC formation in the cat. In the 
three animals studied, IGF-II concentrations did not increase during insulin treatment. We 
speculate that IGF-II may be an important component of binary complexes in cats and more 
readily available to tissues. Nevertheless, we recommend caution in extrapolating what is 
known about the IGF-physiology and pathophysiology between species. 
Predictors of IGF-I during treatment 
In the present study IGF-I concentrations were positively associated with insulin concentrations 
up to 60 ng/mL and negatively associated with fructosamine. In previous studies, weight has 
been associated with IGF-I in health and in diabetes.14,15,31 In this study weight was excluded in 
the final model due to correlation with fructosamine and fructosamine gave a better model fit. 
The association between IGF-I concentrations, fructosamine and insulin needs to be taken into 
account when interpreting IGF-I concentrations and our findings support previous 
recommendations that screening for acromegaly in diabetic cats should be done after initiation 
of adequate therapy.32 
There are likely multiple mechanisms underlying the association between insulin and 
IGF-I concentrations. Our results demonstrated a positive association at insulin concentrations 
up to 60 ng/L which was lost at higher insulin concentrations. Since hepatic GH-receptors will 
stimulate IGF-I synthesis one explanation could be an effect of insulin on hepatic GH-receptor 
expression.33,34 One in vitro study found the effect of insulin on GH-receptor synthesis to be 
dose-dependent, declining at higher insulin concentrations.33 Insulin stimulates ALS 
concentrations35,36 and another possible explanation for the association between IGF-I and 
insulin is an effect of insulin on the circulating forms and therefore half-life of IGF-I. Like IGF-I, 
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ALS is GH dependent1 and any effect on hepatic GH receptors may also play a role in 
regulating its synthesis. 
One cat had very high insulin concentrations when sampled after a year of treatment 
with insulin glargine. The reason for the remarkably high insulin concentration was not 
determined. One possibility is interference of insulin antibodies towards insulin glargine, which 
could be measured in the insulin assay. In humans with DM a rare cause of hyperinsulinemic 
hypoglycemia is insulin antibodies.37 Direct interference of insulin glargine in the assay is 
unlikely given a cross-reactivity of 8.4%, and taking into account the low dose of insulin glargine 
and sampling 12 hours after the injection. 
Prediction of remission 
Glycaemic control is considered the key factor for achieving remission in cats.21,38 In the present 
study, high IGF-I concentrations 2-4 weeks after starting insulin treatment predicted remission of 
DM. Untreated DM may be regarded as a state of intracellular undernutrition. IGF-I 
concentrations are decreased in states of poor nutritional status in cats as well as in 
humans.14,39 It is likely that initiation of insulin therapy increases IGF-I concentrations in part by 
an indirect effect, by promoting anabolism and reducing the catabolic state. It has been 
proposed that local IGF-I promotes survival of feline beta-cells and insulin production.40 IGF-I 
may by enhancing insulin action41 contribute directly to glycaemic control and  therefore 
remission. The finding of increased serum IGF-I concentrations after initiation of insulin 
treatment in cats has been reported previously.12,13 
Because glycaemic control is associated with increased remission rates21 we decided to 
investigate glucose, fructosamine and insulin, in addition to IGF-I, as predictors of remission. 
None of these predictors reached statistical significance or the same AUC as IGF-I in the 
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statistical models. Cats can present with stress hyperglycaemia which may have affected 
glucose measurements in some of the cats,42,43 and could explain why glucose did not perform 
better as a predictor. Fructosamine concentrations are dependent on protein turn-over time and 
blood glucose concentrations and are generally considered to represent glycaemic control 
during the last 1-2 weeks.44,45 It is possible that fructosamine could be a predictor at later time 
points, however there were too few cats left in the study to explore this possibility. In agreement 
with previous reports,10,11 insulin concentrations were not different between the two groups and 
are not useful in the prediction of DM remission in cats. 
Implications for IGF-I as a screening tool for acromegaly 
Although IGF-I concentrations were <1000 ng/mL in all cats at diagnosis, 33% of cats (8/24) 
reached levels >1000 ng/mL while on insulin treatment. This is a similar proportion to that 
reported in a study by Niessen et al.23 None of the 8 cats with IGF-I >1000 ng/mL had clinical 
features of acromegaly and 5/8 cats went into remission, 2/8 cats had fructosamine 
concentrations within the reference interval and 1 cat was euthanized with no findings of 
acromegaly post mortem. However, in the study by Niessen at al23 the majority of cats with DM 
and confirmed acromegaly did not present with phenotypical changes commonly associated 
with acromegaly making clinical features a less reliable diagnostic tool. In the present study, 
acromegaly was only excluded by diagnostic imaging or post mortem examination in 2/5 of cats 
with IGF-I >1000 ng/mL that went into remission from diabetes. Remission from diabetes is 
exclusively described in acromegalic cats after treatment with hypophysectomy46 or 
pasireotide.47. Although we deemed it unlikely that the other three cats had acromegaly, 
however it is theoretically be possibleacromegaly. if insulin resistance was reduced and beta-
cells were still viable. In a recent study acromegaly was diagnosed in 3 cats without DM.48 
Different IGF-I immunoassays may not give the same concentration due to differences in type of 
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calibration material, immunoreactivity and extraction method for IGFBPs which otherwise 
interfere in the assay.15,49  Given these observations we would suggest caution before using 
IGF-I values of 1000 ng/mL as a general cut-off for screening for acromegaly in diabetic cats. 
Strengths and limitations 
Reverse causation and selection bias were minimized by the longitudinal study design, which is 
a clear strength of this study. However, only about one-third of the cats went into remission and 
hence we had low power for the remission prediction models. We did not have access to an 
external validation cohort, which is a limitation because we may be overestimating the AUC. 
The reported remission rate of feline DM is 14-78%.13,21,50-52 The remission rate in this study 
(29%) was in the lower range and may be due to inclusion of cats from both primary care and 
secondary care clinics, which may have differently motivated owners and differences in 
availability of specialists. The near-euglycaemic protocol has been associated with higher 
remission rates in cats21 however the risk of hypoglycaemia may hold back both veterinarians 
and owners from using this approach. The treatment and investigations were decided by the 
treating veterinarians together with the cat owners. Therefore another limitation is that we did 
not perform the same diagnostic work-up in all cats. It is possible that some cats had underlying 
diseases not diagnosed which may affect IGF-I concentrations as well as IGF-binding profiles. 
However animals included in this study are likely to be representative of diabetic cats in general 
practice. Even though the statistical model did not show any significant effect of other diseases, 
only 13 cats with DM had concurrent diseases, making the statistical power low. It is also 
possible that any effect on IGF-I concentrations and IGF-binding profiles may vary with different 
diseases, however there were too few cats to perform these statistical calculations. 
Conclusions 
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In conclusion, IGF-I concentrations increase after initiation of insulin treatment for feline DM and 
were associated with markers of glycaemic control. In cats that went into remission, the amount 
of 150kDa complex and IGFBP-3 increased, suggesting the increase in IGF-I is dependent on 
TC formation. The IGF-I concentration measured 2-4 weeks after initiation of insulin treatment 
shows promise as a predictive marker of remission from DM. 
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Footnotes 
a Glucose, Architect c Systems, Abbott Diagnostics, Illinois, US 
bABX Pentra, Horiba group, Montpellier, France
c Architecht c4000, Abbott Diagnostics, Illinois, US 
d Feline Insulin ELISA, Mercodia, Uppsala, Sweden 
e IGF-I ELISA, Mediagnost, Reutlingen, Germany
f 125I-IGF-II, T-033-23, Phoenix Pharmaceuticals, CA, US
g Superose 12, 17-5173-01, GE Healthcare, Little Chalfont, UK 
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h Wallac Wizard- 2 2470, Perkin Elmer, Massachusetts, US 
i QPrEST, Atlas antibodies, Stockholm, Sweden 
j New England Peptide, Gardner, MA, US 
k EASY-nLC 1000 system, ThermoFisher Scientific, Waltham, MA USA 
l QExactive Plus Orbitrap mass spectrometer, ThermoFisher Scientific, Waltham, MA USA 
m Skyline software, MacCoss Lab Software, University of Washington, Washington state, US 
n The statistical software R. Vienna, Austria: R Foundation for Statistical Computing, URL 
http://www.R-project.org/; 2014: R Foundation for Statistical Computing 
m Lantus, Sanofi AB, Paris, France. 
n Insulatard, Novo Nordisk, Bagsvaerd, Denmark. 
References 
1. Boisclair YR, Rhoads RP, Ueki I, et al. The acid-labile subunit (ALS) of the 150 kDa IGF-
binding protein complex: An important but forgotten component of the circulating IGF system. J 
Endocrinol 2001;170:63-70. 
2. Kelley KM, Oh Y, Gargosky SE, et al. Insulin-like growth factor-binding proteins (IGFBPs)
and their regulatory dynamics. Int J  Biochem Cell Biol 1996;28:619-637. 
3. Baxter RC. Characterization of the acid-labile subunit of the growth hormone-dependent
insulin-like growth factor binding protein complex. J Clin Endocrinol Metab 1988;67:265-272. 
4. Lewitt MS, Hazel SJ, Church DB, et al. Regulation of insulin-like growth factor-binding
protein-3 ternary complex in feline diabetes mellitus. J Endocrinol 2000;166:21-27. 
Page 22 of 32Journal of Veterinary Internal Medicine
23 
5. Niessen SJ, Church DB, Forcada Y. Hypersomatotropism, acromegaly, and 
hyperadrenocorticism and feline diabetes mellitus. The Veterinary clinics of Vet Clin North Am 
Small Anim Pract 2013;43:319-350. 
6. Nelson RW, Reusch CE. Animal models of disease: classification and etiology of diabetes in
dogs and cats. J Endocrinol 2014;222:T1-9. 
7. Zini E, Osto M, Franchini M, et al. Hyperglycaemia but not hyperlipidaemia causes beta cell
dysfunction and beta cell loss in the domestic cat. Diabetologia 2009;52:336-346. 
8. Kirk CA, Feldman EC, Nelson RW. Diagnosis of naturally acquired type-I and type-II
diabetes mellitus in cats. Am J Vet Res 1993;54:463-467. 
9. Strage EM, Holst BS, Nilsson G, et al. Validation of an enzyme-linked immunosorbent assay
for measurement of feline serum insulin. Vet Clin Pathol 2012;41:518-528. 
10. Tschuor F, Zini E, Schellenberg S, et al. Remission of diabetes mellitus in cats cannot be
predicted by the arginine stimulation test. J Vet Intern Med 2011;25:83-89. 
11. Nelson RW, Griffey SM, Feldman EC, et al. Transient clinical diabetes mellitus in cats: 10
cases (1989-1991). J Vet Intern Med 1999;13:28-35. 
12. Reusch CE, Kley S, Casella M, et al. Measurements of growth hormone and insulin-like
growth factor 1 in cats with diabetes mellitus. Vet Rec 2006;158:195-200. 
13. Alt N, Kley S, Tschuor F, et al. Evaluation of IGF-1 levels in cats with transient and
permanent diabetes mellitus. Res Vet Sci 2007;83:331-335. 
14. Maxwell A, Butterwick R, Batt RM, et al. Serum insulin-like growth factor (IGF)-I
concentrations are reduced by short-term dietary restriction and restored by refeeding in 
domestic cats (Felis catus). J Nutr 1999;129:1879-1884. 
15. Strage EM, Theodorsson E, Strom Holst B, et al. Insulin-like growth factor I in cats:
validation of an enzyme-linked immunosorbent assay and determination of biologic variation. 
Vet Clin Pathol 2015;44:542-551. 
Page 23 of 32 Journal of Veterinary Internal Medicine
24 
16. Gilor C, Ridge TK, Attermeier KJ, et al. Pharmacodynamics of insulin detemir and insulin 
glargine assessed by an isoglycemic clamp method in healthy cats. J Vet Intern Med 
2010;24:870-874. 
17. Baldwin K, Bartges J, Buffington T, et al. AAHA Nutritional Assessment Guidelines for Dogs
and Cats. J Am Anim Hosp Assoc 2010;46:285-296. 
18. Mercodia. Feline Insulin ELISA- Directions for Use, 10-1233-01. Uppsala, Sweden. 2008.
19. van Duyvenvoorde HA, Kempers MJ, Twickler TB, et al. Homozygous and heterozygous
expression of a novel mutation of the acid-labile subunit. Eur J Endocrinol 2008;159:113-120. 
20. Sundberg M, Strage EM, Bergquist J, et al. Quantitative and Selective Analysis of Feline
Growth Related Proteins Using Parallel Reaction Monitoring High Resolution Mass 
Spectrometry. PloS one 2016;11:e0167138. 
21. Nack R, DeClue AE. In cats with newly diagnosed diabetes mellitus, use of a near-
euglycemic management paradigm improves remission rate over a traditional paradigm. Vet Q 
2014:1-5. 
22. Rosca M, Forcada Y, Solcan G, et al. Screening diabetic cats for hypersomatotropism:
performance of an enzyme-linked immunosorbent assay for insulin-like growth factor 1. J Feline 
Med Surg 2014;16:82-88. 
23. Niessen SJ, Forcada Y, Mantis P, et al. Studying Cat (Felis catus) Diabetes: Beware of the
Acromegalic Imposter. PloS one 2015;10:e0127794. 
24. Rucinsky R, Cook A, Haley S, et al. AAHA diabetes management guidelines. J Am Anim
Hosp Assoc 2010;46:215-224. 
25. Baxter RC. Insulin-like growth factor (IGF) binding proteins: the role of serum IGFBPs in
regulating IGF availability. Acta paediatr Scand Suppl 1991;372:107-114; discussion 115. 
26. Twigg SM, Baxter RC. Insulin-like growth factor (IGF)-binding protein 5 forms an alternative
ternary complex with IGFs and the acid-labile subunit. J Biol Chem 1998;273:6074-6079. 
Page 24 of 32Journal of Veterinary Internal Medicine
25 
27. Scaglia PA, Keselman AC, Braslavsky D, et al. Characterization of four Latin American 
families confirms previous findings and reveals novel features of acid-labile subunit deficiency. 
Clin Endocrinol (Oxf) 2017. 
28. Lewitt MS, Brismar K, Wang J, et al. Responses of insulin-like growth factor (IGF)-I and
IGF-binding proteins to nutritional status in peroxisome proliferator-activated receptor-alpha 
knockout mice. Growth Horm IGF Res 2001;11:303-313. 
29. Renes JS, van Doorn J, Hokken-Koelega AC. Ternary complex formation and IGFBP-3
proteolytic activity during childhood: age-dependent changes. J Clin Endocrinol Metab 
2014;99:E1988-1996. 
30. Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factor-binding proteins in serum and
other biological fluids: regulation and functions. Endocr Rev 1997;18:801-831. 
31. Berg RI, Nelson RW, Feldman EC, et al. Serum insulin-like growth factor-I concentration in
cats with diabetes mellitus and acromegaly. J Vet Intern Med 2007;21:892-898. 
32. Greco DS. Feline acromegaly. Top Companion Anim Med 2012;27:31-35.
33. Leung KC, Doyle N, Ballesteros M, et al. Insulin regulation of human hepatic growth
hormone receptors: Divergent effects on biosynthesis and surface translocation. J Clin 
Endocrinol Metab 2000;85:4712-4720. 
34. Baxter RC, Bryson JM, Turtle JR. Somatogenic receptors of rat liver: Regulation by insulin.
Endocrinology 1980;107:1176-1181. 
35. Dai J, Scott CD, Baxter RC. Regulation of the acid-labile subunit of the insulin-like growth
factor complex in cultured rat hepatocytes. Endocrinology 1994;135:1066-1072. 
36. Dai J, Baxter RC. Regulation in vivo of the acid-labile subunit of the rat serum insulin-like
growth factor-binding protein complex. Endocrinology 1994;135:2335-2341. 
37. Su CT, Lin YC. Hyperinsulinemic hypoglycemia associated with insulin antibodies caused
by exogenous insulin analog. Endocrinol Diabetes Metab Case Rep 2016;2016. 
Page 25 of 32 Journal of Veterinary Internal Medicine
26 
38. Gottlieb S, Rand JS. Remission in cats: including predictors and risk factors. Vet Clin North 
Am Small Anim Pract 2013;43:245-249. 
39. Livingstone C. Insulin-like growth factor-I (IGF-I) and clinical nutrition. Clinical science
2013;125:265-280. 
40. Link KR, Allio I, Rand JS, et al. The effect of experimentally induced chronic
hyperglycaemia on serum and pancreatic insulin, pancreatic islet IGF-I and plasma and urinary 
ketones in the domestic cat (Felis felis). Gen Comp Endocrinol 2013;188:269-281. 
41. Clemmons DR. Metabolic Actions of Insulin-Like Growth Factor-I in Normal Physiology and
Diabetes. Endocrinol Metab Clin North Am 2012;41:425-443. 
42. Laluha P, Gerber B, Laluhová D, et al. Stress hyperglycemia in sick cats: A retrospective
study over 4 years. Schweiz Arch Tierheilkd 2004;146:375-383. 
43. Rand JS, Kinnaird E, Baglioni A, et al. Acute stress hyperglycemia in cats is associated with
struggling and increased concentrations of lactate and norepinephrine. J Vet Intern Med 
2002;16:123-132. 
44. Link KR, Rand JS. Changes in blood glucose concentration are associated with relatively
rapid changes in circulating fructosamine concentrations in cats. J Feline Med Surg 
2008;10:583-592. 
45. Crenshaw KL, Peterson ME, Heeb LA, et al. Serum fructosamine concentration as an index
of glycemia in cats with diabetes mellitus and stress hyperglycemia. J Vet Intern Med 
1996;10:360-364. 
46. Meij BP, Auriemma E, Grinwis G, et al. Successful treatment of acromegaly in a diabetic cat
with transsphenoidal hypophysectomy. J Feline Med Surg 2010;12:406-410. 
47. Gostelow R, Scudder C, Keyte S, et al. Pasireotide Long-Acting Release Treatment for
Diabetic Cats with Underlying Hypersomatotropism. J Vet Intern Med 2017;31:355-364. 
48. Fletcher JM, Scudder CJ, Kiupel M, et al. Hypersomatotropism in 3 Cats without Concurrent
Diabetes Mellitus. J Vet Intern Med 2016;30:1216-1221. 
Page 26 of 32Journal of Veterinary Internal Medicine
27 
49. Tschuor F, Zini E, Schellenberg S, et al. Evaluation of four methods used to measure 
plasma insulin-like growth factor 1 concentrations in healthy cats and cats with diabetes mellitus 
or other diseases. Am J Vet Res 2012;73:1925-1931. 
50. Hafner M, Dietiker-Moretti S, Kaufmann K, et al. Intensive intravenous infusion of insulin in
diabetic cats. J Vet Intern Med 2014;28:1753-1759. 
51. Hall TD, Mahony O, Rozanski EA, et al. Effects of diet on glucose control in cats with
diabetes mellitus treated with twice daily insulin glargine. J Feline Med Surg 2009;11:125-130. 
52. Michiels L, Reusch CE, Boari A, et al. Treatment of 46 cats with porcine lente insulin--a
prospective, multicentre study. J Feline Med Surg 2008;10:439-451. 
Page 27 of 32 Journal of Veterinary Internal Medicine
28 









10-13 months (T4) 
(n=11) 
IGF-I (ng/mL) 300 (160, 556) 670 (281, 1044) 562 (359, 926) 484 (306, 811) 444 (339, 743) 
Fructosamine (µmol/L) 591 (545, 746) 524 (456, 607) 489 (340, 590) 520 (436, 578) 414 (286, 505) 
Glucose (mg/dL) 414 (330, 501) 286 (182, 517) 265 (133, 434) 351 (223, 425) 105 (74, 382) 
Insulin (ng/L) 42 (21, 81) 52 (30, 112) 85 (29, 226) 94 (35, 243) 39 (32, 547) 
Weight (kg) 5.2 (4.3, 5.8) 5.4 (4.6, 6.0) 5.8 (4.7, 6.0) 5.8 (5.4, 6.5) 6.0 (5.0, 7.1) 
Age (years) 11.0 (9.4, 12.7) 10.9 (9.3, 12.8) 10.9 (8.8, 12.4) 10.8 (8.9, 12.2) 11.3 (8.9, 12.2) 
Insulin dosage (IU/kg) N/A 0.3 (0.2, 0.4) 0.5 (0.2, 0.6) 0.4 (0.3, 0.6) 0.4 (0.3, 0.6) 
N/A not applicable















Table 2. Linear mixed model analysis with IGF-I concentrations as the dependent variable in 24 
cats with diabetes mellitus sampled up to five times during insulin treatment. The variance 
explained of the model (R2adj) was 0.3.1  
Predictor β (95% CI) P 
Ln fructosamine -489.5 (-670, -300) <0.0001 
Ln insulin 137.6* (44, 230) 0.005 
Age (years) 36.3 (0, 73) 0.052 
*The association was seen up to insulin concentrations of 60 ng/L
1. The variance explained of the model (R2adj) was 0.3 disregarding the random effect for cat 
identity. 
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Legends 
Figure 1. Flow-chart of study design. 
Figure 2. IGF-binding profiles after size-separation in healthy and diabetic cats sampled before 
insulin treatment after incubation with human 125I-IGF-II. Cats were grouped according to their 
IGF-I concentration analyzed with an IGF-I ELISA. Bars are presented as mean and standard 
error of the mean. 
Figure 3. Scatterplot of 150/30-50kDa-ratio and IGF-I concentrations in 13 healthy (filled circles) 
and 13 diabetic cats sampled before insulin treatment (open circles). 
Figure 4. Concentrations of IGF-I (A), fructosamine (B), insulin (C) and glucose (D) during the 
treatment of feline diabetes mellitus. Values are expressed as the median and interquartile 
range for 24 cats. Black circles with solid lines are cats which go into remission (T0: n=7, T1: 
n=6, T2: n=3) and open circles with broken lines are cats which do not go into remission (T0: 
n=17, T1: n=16, T2: n=14, T3: n=14, T4: n=11). 
* Sample at remission is taken at least one month after insulin was withdrawn.
** One cat at T4 had insulin concentrations much higher than the others (7903 ng/L) and is not 
included in the graph. 
Figure 5. Distribution of IGF-binding forms in three cats which went into remission, sampled 
before treatment, T0 (A) and at 2-4 weeks after insulin therapy, T1 (B). Serum was size 
separated on a Superose 12 column after incubated with human 125I-IGF-II as described in
material and methods. Results are expressed as counts per minute (C.P.M.). IGF-I,-II, IGFBP-3 
and IGFBP-5 were measure by mass spectrometry.  
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Figure 6. Distribution of IGF-binding forms in four cats which did not achieve remission sampled 
before treatment, T0 (A) and at 2-4 weeks after insulin therapy, T1 (B). Serum was size 
separated on a Superose 12 column after incubated with human 125I-IGF-II as described in 
material and methods. Results are expressed as counts per minute (C.P.M., mean ± SEM). 
Figure 7. Receiver operating characteristic curves discriminating between cats going into 
remission or not. The curves were derived from 22 diabetic cats sampled 2-4 weeks after 
starting insulin treatment. Of these cats 6 went into remission. Area under the curve (AUC) and 
95% confidence interval are indicated on the graphs. 
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